Opinion

Video

Other Investigational Drug Delivery Systems in NMIBC

Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102.

Video Player is loading.
Current Time 0:00
Duration 2:55
Loaded: 5.61%
Stream Type LIVE
Remaining Time 2:55
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following:

    • Please briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk NMIBC. What are your impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102?

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Related Content
    © 2025 MJH Life Sciences

    All rights reserved.